Fortress Biotech to Participate in October 2024 Investor Conferences

Rhea-AI Summary

Fortress Biotech, a biopharmaceutical company focused on acquiring and advancing assets, announced its participation in two upcoming investor conferences in October 2024. Lindsay A. Rosenwald, M.D., the company's Chairman, President, and CEO, will represent Fortress at these events:

1. Lytham Partners Fall 2024 Investor Conference on October 1, 2024, at 4:15 p.m. ET. This virtual event will feature a fireside chat and 1x1 meetings.

2. 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024, in New York, consisting of 1x1 meetings.

A replay of the Lytham Partners fireside chat will be available on Fortress Biotech's website for approximately 30 days after the event.

MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in the following upcoming October 2024 investor conferences:

Lytham Partners Fall 2024 Investor Conference
Date and Time: Tuesday, October 1, 2024 at 4:15 p.m. ET
Location: Virtual
Format: Fireside Chat and 1x1 Meetings
Registration link for the event: https://lythampartners.com/fall2024invreg

3^rd Annual ROTH Healthcare Opportunities Conference
Date: Wednesday, October 9, 2024
Location: New York
Format: 1x1 Meetings

A replay of the fireside chat at the Lytham Partners Fall 2024 Investor Conference will be available shortly after the conference on the Events page under the News & Media section of Fortress’ website: www.fortressbiotech.com for approximately 30 days following the meeting.

About Fortress Biotech

Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue. The company has seven marketed prescription pharmaceutical products and over 20 programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Fred Hutchinson Cancer Center, Nationwide Children’s Hospital and Sentynl. For more information, visit www.fortressbiotech.com.

Company Contact:
Jaclyn Jaffe
Fortress Biotech, Inc.
(781) 652-4500
ir@fortressbiotech.com

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com

FAQ

When is Fortress Biotech (FBIO) participating in the Lytham Partners Fall 2024 Investor Conference?

Fortress Biotech (FBIO) is participating in the Lytham Partners Fall 2024 Investor Conference on Tuesday, October 1, 2024, at 4:15 p.m. ET.

What is the format of Fortress Biotech's (FBIO) participation in the Lytham Partners Fall 2024 Investor Conference?

Fortress Biotech (FBIO) will participate in a fireside chat and 1x1 meetings at the Lytham Partners Fall 2024 Investor Conference, which will be held in a virtual format.

When and where is Fortress Biotech (FBIO) attending the 3rd Annual ROTH Healthcare Opportunities Conference?

Fortress Biotech (FBIO) is attending the 3rd Annual ROTH Healthcare Opportunities Conference on Wednesday, October 9, 2024, in New York.

Who will represent Fortress Biotech (FBIO) at the October 2024 investor conferences?

Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer of Fortress Biotech (FBIO), will represent the company at the October 2024 investor conferences.

How long will the replay of Fortress Biotech's (FBIO) fireside chat at the Lytham Partners conference be available?

The replay of Fortress Biotech's (FBIO) fireside chat at the Lytham Partners Fall 2024 Investor Conference will be available on the company's website for approximately 30 days following the event.